New Trial: iPSC-Derived Exosome Therapy for Moyamoya Disease
Researchers are testing whether exosomes from stem cells can enhance blood vessel repair for Moyamoya patients after surgery.
Cardiovascular
Longeveron Gains FDA Approval to Begin Phase 2 Stem Cell Trial for Children with Heart Disease
Longeveron will evaluate if it's stem cell candidate, laromestrocel, could target pediatric dilated cardiomyopathy
Ensoma nabs IND from the FDA for first in-vivo HSC-directed gene insertion therapy
With FDA approval secured, Ensoma prepares to advance its groundbreaking in vivo therapy into clinical trials targeting X-CGD patients.
Organ donor? That may include using your stem cells: first successful transplant using deceased donor in blood Cancer clinical trial
It's interesting to consider, much like with umbilical cords, how often are we incinerating life-saving stem cells?
Hematopoietic Stem Cell-Directed Gene Insertion Therapy Gets IND Clearance
With FDA clearance secured, Ensoma prepares to launch its Phase 1/2 clinical trial to establish safety, efficacy, and dosing.
Safety and Efficacy of Epicardial Implantation of Collagen Membranes with Allogeneic Adipose-Derived Stem Cells (Cardiomesh)
This study will evaluate if the VB-C01 cellularised patch, a collagen membrane seeded with allogeneic adipose-derived stem cells, is safe and effective for surgical epicardial implantation in patients undergoing coronary artery bypass...
Off-the-shelf stem cells for heart failure: Trial reports positive results, independent board recommends moving forward with using BioCardia’s CardiALLO
BioCardia plans to move forward with enrollment of up to 39 participants in the United States.
BioGenCell Nabs FDA Fast Track Designation for Critical Limb Threatening Ischemia Cell Therapy, BGC101
BioGenCell's lead candidate BGC101 receives FDA Fast Track Designation, accelerating development of its personalized cell therapy to prevent amputations in severe CLTI patients.
Japan startup applies for approval of iPS cell therapy for heart disease
Clinical trials involving eight patients showed improvements in symptoms and cardiac function.
Garuda Therapeutics Nabs $50 Million Series A-1 Financing for Off-the-Shelf Blood Stem Cell Therapies
New funds aim to advance Garuda’s pipeline toward clinical trials, expand manufacturing capabilities, and support operational growth.
